PLX Protalix BioTherapeutics Inc

Price (delayed)

$0.8134

Market cap

$37.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$63.14M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
Protalix BioTherapeutics's quick ratio has surged by 55% QoQ and by 26% YoY
PLX's debt is down by 42% YoY and by 41% from the previous quarter
PLX's EPS has dropped by 200% year-on-year but it is up by 10% since the previous quarter
Protalix BioTherapeutics's equity has surged by 101% YoY but it has shrunk by 94% QoQ
The gross profit has declined by 33% year-on-year
Protalix BioTherapeutics's gross margin has decreased by 17% YoY

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
45.56M
Market cap
$37.06M
Enterprise value
$63.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
173.97
Price to sales (P/S)
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.28
Earnings
Revenue
$49.3M
EBIT
-$11.87M
EBITDA
-$10.72M
Free cash flow
-$13.98M
Per share
EPS
-$0.45
Free cash flow per share
-$0.31
Book value per share
$0
Revenue per share
$1.08
TBVPS
$1.83
Balance sheet
Total assets
$83.48M
Total liabilities
$83.27M
Debt
$36.73M
Equity
$213,000
Working capital
$28.46M
Liquidity
Debt to equity
172.45
Current ratio
1.67
Quick ratio
1.27
Net debt/EBITDA
-2.43
Margins
EBITDA margin
-21.7%
Gross margin
67.6%
Net margin
-41.6%
Operating margin
-24.2%
Efficiency
Return on assets
-22.6%
Return on equity
N/A
Return on invested capital
-24%
Return on capital employed
-29.1%
Return on sales
-24.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-4.31%
1 week
-17.84%
1 month
-30.48%
1 year
-76.63%
YTD
-77.59%
QTD
-38.84%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$49.3M
Gross profit
$33.34M
Operating income
-$11.92M
Net income
-$20.52M
Gross margin
67.6%
Net margin
-41.6%
The gross profit has declined by 33% year-on-year
Protalix BioTherapeutics's revenue has decreased by 19% YoY but it has increased by 2.6% from the previous quarter
Protalix BioTherapeutics's gross margin has decreased by 17% YoY
The operating margin has increased by 8% from the previous quarter

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
173.97
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.28
PLX's EPS has dropped by 200% year-on-year but it is up by 10% since the previous quarter
Protalix BioTherapeutics's equity has surged by 101% YoY but it has shrunk by 94% QoQ
PLX's price to sales (P/S) is 77% lower than its 5-year quarterly average of 3.2 and 63% lower than its last 4 quarters average of 2.0
Protalix BioTherapeutics's revenue has decreased by 19% YoY but it has increased by 2.6% from the previous quarter

Efficiency

How efficient is Protalix BioTherapeutics business performance
The ROA has plunged by 133% YoY but it has grown by 4.2% from the previous quarter
PLX's return on sales is up by 8% since the previous quarter

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
The company's current ratio has surged by 67% QoQ and by 22% YoY
Protalix BioTherapeutics's quick ratio has surged by 55% QoQ and by 26% YoY
Protalix BioTherapeutics's equity has surged by 101% YoY but it has shrunk by 94% QoQ
PLX's debt is down by 42% YoY and by 41% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.